Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents
• Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted ag...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Iacovelli, Roberto [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: miR-214 in stroma cells and tumor progression - Dettori, D. ELSEVIER, 2016, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:99 ; year:2016 ; pages:324-331 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.critrevonc.2016.01.014 |
|---|
| Katalog-ID: |
ELV029989515 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV029989515 | ||
| 003 | DE-627 | ||
| 005 | 20230623203318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2016.01.014 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016018000015.pica |
| 035 | |a (DE-627)ELV029989515 | ||
| 035 | |a (ELSEVIER)S1040-8428(16)30010-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.52 |2 bkl | ||
| 100 | 1 | |a Iacovelli, Roberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents |
| 264 | 1 | |c 2016 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients. | ||
| 650 | 7 | |a Second line |2 Elsevier | |
| 650 | 7 | |a Phase III trial |2 Elsevier | |
| 650 | 7 | |a MRCC |2 Elsevier | |
| 650 | 7 | |a Sunitinib |2 Elsevier | |
| 650 | 7 | |a First line |2 Elsevier | |
| 650 | 7 | |a Sorafenib |2 Elsevier | |
| 650 | 7 | |a Phase II trial |2 Elsevier | |
| 650 | 7 | |a Axitinib |2 Elsevier | |
| 650 | 7 | |a Tivozanib |2 Elsevier | |
| 700 | 1 | |a Verri, Elena |4 oth | |
| 700 | 1 | |a Cossu Rocca, Maria |4 oth | |
| 700 | 1 | |a Aurilio, Gaetano |4 oth | |
| 700 | 1 | |a Cullurà, Daniela |4 oth | |
| 700 | 1 | |a Santoni, Matteo |4 oth | |
| 700 | 1 | |a de Cobelli, Ottavio |4 oth | |
| 700 | 1 | |a Nolé, Franco |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Dettori, D. ELSEVIER |t miR-214 in stroma cells and tumor progression |d 2016 |g Amsterdam [u.a.] |w (DE-627)ELV019637179 |
| 773 | 1 | 8 | |g volume:99 |g year:2016 |g pages:324-331 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.critrevonc.2016.01.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2016 | ||
| 912 | |a GBV_ILN_2048 | ||
| 936 | b | k | |a 44.52 |j Therapie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 99 |j 2016 |h 324-331 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
r i ri |
|---|---|
| matchkey_str |
iacovellirobertoverrielenacossuroccamari:2016----:shrsilrlfroaeiimtsairnlelacnmaytmtceiwnmtaayiotefetv |
| hierarchy_sort_str |
2016 |
| bklnumber |
44.52 |
| publishDate |
2016 |
| allfields |
10.1016/j.critrevonc.2016.01.014 doi GBVA2016018000015.pica (DE-627)ELV029989515 (ELSEVIER)S1040-8428(16)30010-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Iacovelli, Roberto verfasserin aut Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients. Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib Elsevier Verri, Elena oth Cossu Rocca, Maria oth Aurilio, Gaetano oth Cullurà, Daniela oth Santoni, Matteo oth de Cobelli, Ottavio oth Nolé, Franco oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:99 year:2016 pages:324-331 extent:8 https://doi.org/10.1016/j.critrevonc.2016.01.014 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 99 2016 324-331 8 045F 610 |
| spelling |
10.1016/j.critrevonc.2016.01.014 doi GBVA2016018000015.pica (DE-627)ELV029989515 (ELSEVIER)S1040-8428(16)30010-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Iacovelli, Roberto verfasserin aut Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients. Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib Elsevier Verri, Elena oth Cossu Rocca, Maria oth Aurilio, Gaetano oth Cullurà, Daniela oth Santoni, Matteo oth de Cobelli, Ottavio oth Nolé, Franco oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:99 year:2016 pages:324-331 extent:8 https://doi.org/10.1016/j.critrevonc.2016.01.014 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 99 2016 324-331 8 045F 610 |
| allfields_unstemmed |
10.1016/j.critrevonc.2016.01.014 doi GBVA2016018000015.pica (DE-627)ELV029989515 (ELSEVIER)S1040-8428(16)30010-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Iacovelli, Roberto verfasserin aut Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients. Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib Elsevier Verri, Elena oth Cossu Rocca, Maria oth Aurilio, Gaetano oth Cullurà, Daniela oth Santoni, Matteo oth de Cobelli, Ottavio oth Nolé, Franco oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:99 year:2016 pages:324-331 extent:8 https://doi.org/10.1016/j.critrevonc.2016.01.014 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 99 2016 324-331 8 045F 610 |
| allfieldsGer |
10.1016/j.critrevonc.2016.01.014 doi GBVA2016018000015.pica (DE-627)ELV029989515 (ELSEVIER)S1040-8428(16)30010-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Iacovelli, Roberto verfasserin aut Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients. Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib Elsevier Verri, Elena oth Cossu Rocca, Maria oth Aurilio, Gaetano oth Cullurà, Daniela oth Santoni, Matteo oth de Cobelli, Ottavio oth Nolé, Franco oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:99 year:2016 pages:324-331 extent:8 https://doi.org/10.1016/j.critrevonc.2016.01.014 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 99 2016 324-331 8 045F 610 |
| allfieldsSound |
10.1016/j.critrevonc.2016.01.014 doi GBVA2016018000015.pica (DE-627)ELV029989515 (ELSEVIER)S1040-8428(16)30010-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.52 bkl Iacovelli, Roberto verfasserin aut Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients. Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib Elsevier Verri, Elena oth Cossu Rocca, Maria oth Aurilio, Gaetano oth Cullurà, Daniela oth Santoni, Matteo oth de Cobelli, Ottavio oth Nolé, Franco oth Enthalten in Elsevier Science Dettori, D. ELSEVIER miR-214 in stroma cells and tumor progression 2016 Amsterdam [u.a.] (DE-627)ELV019637179 volume:99 year:2016 pages:324-331 extent:8 https://doi.org/10.1016/j.critrevonc.2016.01.014 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 44.52 Therapie Medizin VZ AR 99 2016 324-331 8 045F 610 |
| language |
English |
| source |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:99 year:2016 pages:324-331 extent:8 |
| sourceStr |
Enthalten in miR-214 in stroma cells and tumor progression Amsterdam [u.a.] volume:99 year:2016 pages:324-331 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Therapie |
| institution |
findex.gbv.de |
| topic_facet |
Second line Phase III trial MRCC Sunitinib First line Sorafenib Phase II trial Axitinib Tivozanib |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
miR-214 in stroma cells and tumor progression |
| authorswithroles_txt_mv |
Iacovelli, Roberto @@aut@@ Verri, Elena @@oth@@ Cossu Rocca, Maria @@oth@@ Aurilio, Gaetano @@oth@@ Cullurà, Daniela @@oth@@ Santoni, Matteo @@oth@@ de Cobelli, Ottavio @@oth@@ Nolé, Franco @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV019637179 |
| dewey-sort |
3610 |
| id |
ELV029989515 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029989515</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623203318.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2016.01.014</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029989515</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(16)30010-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Iacovelli, Roberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Second line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Phase III trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MRCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sunitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">First line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sorafenib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Phase II trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Axitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tivozanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verri, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cossu Rocca, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aurilio, Gaetano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cullurà, Daniela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Matteo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Cobelli, Ottavio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nolé, Franco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:99</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:324-331</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2016.01.014</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">99</subfield><subfield code="j">2016</subfield><subfield code="h">324-331</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Iacovelli, Roberto |
| spellingShingle |
Iacovelli, Roberto ddc 610 bkl 44.52 Elsevier Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents |
| authorStr |
Iacovelli, Roberto |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV019637179 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.52 bkl Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib Elsevier |
| topic |
ddc 610 bkl 44.52 Elsevier Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib |
| topic_unstemmed |
ddc 610 bkl 44.52 Elsevier Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib |
| topic_browse |
ddc 610 bkl 44.52 Elsevier Second line Elsevier Phase III trial Elsevier MRCC Elsevier Sunitinib Elsevier First line Elsevier Sorafenib Elsevier Phase II trial Elsevier Axitinib Elsevier Tivozanib |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e v ev r m c rm rmc g a ga d c dc m s ms c o d co cod f n fn |
| hierarchy_parent_title |
miR-214 in stroma cells and tumor progression |
| hierarchy_parent_id |
ELV019637179 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
miR-214 in stroma cells and tumor progression |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV019637179 |
| title |
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents |
| ctrlnum |
(DE-627)ELV029989515 (ELSEVIER)S1040-8428(16)30010-5 |
| title_full |
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents |
| author_sort |
Iacovelli, Roberto |
| journal |
miR-214 in stroma cells and tumor progression |
| journalStr |
miR-214 in stroma cells and tumor progression |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
324 |
| author_browse |
Iacovelli, Roberto |
| container_volume |
99 |
| physical |
8 |
| class |
610 610 DE-600 610 VZ 44.52 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Iacovelli, Roberto |
| doi_str_mv |
10.1016/j.critrevonc.2016.01.014 |
| dewey-full |
610 |
| title_sort |
is there still a role for sorafenib in metastatic renal cell carcinoma? a systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents |
| title_auth |
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents |
| abstract |
• Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients. |
| abstractGer |
• Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients. |
| abstract_unstemmed |
• Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_11 GBV_ILN_20 GBV_ILN_70 GBV_ILN_100 GBV_ILN_2006 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2016 GBV_ILN_2048 |
| title_short |
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents |
| url |
https://doi.org/10.1016/j.critrevonc.2016.01.014 |
| remote_bool |
true |
| author2 |
Verri, Elena Cossu Rocca, Maria Aurilio, Gaetano Cullurà, Daniela Santoni, Matteo de Cobelli, Ottavio Nolé, Franco |
| author2Str |
Verri, Elena Cossu Rocca, Maria Aurilio, Gaetano Cullurà, Daniela Santoni, Matteo de Cobelli, Ottavio Nolé, Franco |
| ppnlink |
ELV019637179 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.critrevonc.2016.01.014 |
| up_date |
2024-07-06T22:54:24.505Z |
| _version_ |
1803872071326892032 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029989515</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623203318.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.critrevonc.2016.01.014</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016018000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029989515</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1040-8428(16)30010-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.52</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Iacovelli, Roberto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Other targeted agents decrease the risk of progression compared to sorafenib. • Other targeted agents increase the response rate compared to sorafenib. • But no difference in PFS were found in the intermediate risk prognosis. • No difference were found in OS between sorafenib and other targeted agents. • Sorafenib might be an option for certain mRCC patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Second line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Phase III trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MRCC</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sunitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">First line</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sorafenib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Phase II trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Axitinib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Tivozanib</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verri, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cossu Rocca, Maria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aurilio, Gaetano</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cullurà, Daniela</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Santoni, Matteo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Cobelli, Ottavio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nolé, Franco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Dettori, D. ELSEVIER</subfield><subfield code="t">miR-214 in stroma cells and tumor progression</subfield><subfield code="d">2016</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV019637179</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:99</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:324-331</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.critrevonc.2016.01.014</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2016</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.52</subfield><subfield code="j">Therapie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">99</subfield><subfield code="j">2016</subfield><subfield code="h">324-331</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4022274 |